0MGB.IL - Genmab A/S
Genmab A/S
Kalvebod Brygge 43
Copenhagen 1560
Denmark
45 70 20 27 28
https://www.genmab.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 1,846
Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Dr. Jan G.J. van de Winkel Ph.D. | Co-Founder, Pres & CEO | 18.8M | N/A | 1961 |
| Mr. Anthony Pagano | Exec. VP & CFO | 7M | N/A | 1978 |
| Mr. Anthony Mancini | Exec. VP & COO | 7.6M | N/A | 1971 |
| Mr. Martin Schultz | Sr. Director of Clinical Operations & Non-Independent Director | 500k | N/A | 1976 |
| Dr. Judith V. Klimovsky M.D. | Exec. VP & Chief Devel. Officer | 7.9M | N/A | 1958 |
| Dr. Tahamtan Ahmadi | Exec. VP, Chief Medical Officer & Head of Experimental Medicines | 7.5M | N/A | 1973 |
| Dr. Mijke Zachariasse Ph.D. | Sr. Director, Head of Antibody Research Materials & Non-Independent Director | 1M | N/A | 1974 |
| Mr. Takahiro Hamatani | Sr. Director of Fin. Japan & Non-Independent Director | 500k | N/A | 1975 |
| Mr. Andrew Carlsen | Sr. Director, VP & Head of Investor Relations | N/A | N/A | N/A |
| Ms. Birgitte Stephensen M.Sc. | Exec. VP & Chief Legal Officer | N/A | N/A | 1961 |
Description
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumurnab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and DuoHexaBody-CD37 for treating hematological malignancies. The company also develops Teclistamab, which is in Phase 2 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with CureVac AG for the research and development of differentiated mRNA-based antibody products; argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, Novo Nordisk A/S, BliNK Biomedical SAS, and Bolt Biotherapeutics, Inc. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Corporate Governance
Genmab A/S’s ISS Governance QualityScore as of May 30, 2023 is 1. The pillar scores are Audit: 1; Board: 1; Shareholder Rights: 1; Compensation: 3.
